Payment overview · 2025
General Payments
$400.28
23 reported records · 11 companies
Healthcare provider profile · identity verified
Gary E Okuley, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · DEFIANCE, OH · NPI 1144211558
Verified facts
What the public records show
CMS Open Payments records show Gary E Okuley, M.D. received $400.28 in general payments during 2025 across 23 reported records.
ABBVIE INC. accounted for 24.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 495 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $97.83 | 24.4% | 6 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $56.79 | 14.2% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $40.75 | 10.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $37.18 | 9.3% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $36.02 | 9.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $33.89 | 8.5% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $33.74 | 8.4% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $17.05 | 4.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.33 | 4.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.81 | 4.0% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.89 | 3.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $400.28 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $61.67 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $61.67 | 4 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $56.79 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $40.75 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $37.18 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $36.16 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $36.02 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $36.02 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $33.89 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $20.19 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.59 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $17.05 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.33 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $16.30 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.81 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $14.89 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $13.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 495 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
39 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
69 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
495 | 50 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 834 | 194 |
| Eliquis | Apixaban | 495 | 50 |
| Metoprolol Succinate | Metoprolol Succinate | 492 | 126 |
| Omeprazole | Omeprazole | 475 | 112 |
| Lisinopril | Lisinopril | 454 | 109 |
| Furosemide | Furosemide | 441 | 72 |
| Metoprolol Tartrate | Metoprolol Tartrate | 436 | 99 |
| Sertraline Hcl | Sertraline Hcl | 426 | 74 |
| Amlodipine Besylate | Amlodipine Besylate | 414 | 95 |
| Levothyroxine Sodium | Levothyroxine Sodium | 397 | 84 |
| Losartan Potassium | Losartan Potassium | 350 | 64 |
| Metformin Hcl | Metformin Hcl | 313 | 59 |
| Potassium Chloride | Potassium Chloride | 310 | 67 |
| Simvastatin | Simvastatin | 304 | 75 |
| Gabapentin | Gabapentin | 301 | 54 |
| Hydrochlorothiazide | Hydrochlorothiazide | 298 | 75 |
| Tamsulosin Hcl | Tamsulosin Hcl | 290 | 67 |
| Clopidogrel | Clopidogrel Bisulfate | 281 | 62 |
| Trazodone Hcl | Trazodone Hcl | 243 | 43 |
| Buspirone Hcl | Buspirone Hcl | 232 | 30 |
| Famotidine | Famotidine | 214 | 43 |
| Warfarin Sodium | Warfarin Sodium | 214 | 22 |
| Glimepiride | Glimepiride | 207 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 204 | 44 |
| Mirtazapine | Mirtazapine | 169 | 31 |
| Donepezil Hcl | Donepezil Hcl | 166 | 27 |
| Meloxicam | Meloxicam | 159 | 38 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 157 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 153 | 24 |
| Prednisone | Prednisone | 150 | 90 |
| Carvedilol | Carvedilol | 141 | 29 |
| Allopurinol | Allopurinol | 131 | 32 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 131 | 49 |
| Escitalopram Oxalate | Escitalopram Oxalate | 120 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 118 | 43 |
| Pravastatin Sodium | Pravastatin Sodium | 116 | 25 |
| Cephalexin | Cephalexin | 114 | 31 |
| Montelukast Sodium | Montelukast Sodium | 114 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 100 | 42 |
| Tramadol Hcl | Tramadol Hcl | 92 | 27 |
| Spironolactone | Spironolactone | 90 | 19 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 89 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 88 | 25 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 88 | 43 |
| Lorazepam | Lorazepam | 86 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 78 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 78 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 76 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 76 | 21 |
| Bupropion Xl | Bupropion Hcl | 74 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 72 | 17 |
| Permethrin | Permethrin | 71 | 42 |
| Januvia | Sitagliptin Phosphate | 70 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 69 | suppressed |
| Ezetimibe | Ezetimibe | 69 | 15 |
| Memantine Hcl | Memantine Hcl | 69 | suppressed |
| Ozempic | Semaglutide | 69 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 69 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 65 | 31 |
| Sucralfate | Sucralfate | 64 | 14 |
| Nyamyc | Nystatin | 63 | 27 |
| Doxycycline Hyclate | Doxycycline Hyclate | 60 | 24 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 60 | 15 |
| Azithromycin | Azithromycin | 58 | 52 |
| Finasteride | Finasteride | 58 | suppressed |
| Klor-Con M20 | Potassium Chloride | 58 | 16 |
| Baclofen | Baclofen | 57 | 11 |
| Fenofibrate | Fenofibrate | 57 | 18 |
| Alprazolam | Alprazolam | 55 | 24 |
| Amiodarone Hcl | Amiodarone Hcl | 52 | suppressed |
| Myrbetriq | Mirabegron | 52 | suppressed |
| Bumetanide | Bumetanide | 51 | 15 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 50 | 12 |
| Lactulose | Lactulose | 50 | 16 |
| Nystatin | Nystatin | 50 | 28 |
| Albuterol Sulfate | Albuterol Sulfate | 48 | 12 |
| Tradjenta | Linagliptin | 48 | suppressed |
| Jardiance | Empagliflozin | 47 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 47 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 47 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 46 | 11 |
| Risperidone | Risperidone | 46 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 45 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 44 | 31 |
| Novolog Flexpen | Insulin Aspart | 44 | 13 |
| Terazosin Hcl | Terazosin Hcl | 44 | suppressed |
| Celecoxib | Celecoxib | 41 | 11 |
| Digoxin | Digoxin | 41 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 41 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 40 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 39 | 14 |
| Synthroid | Levothyroxine Sodium | 39 | 11 |
| Linzess | Linaclotide | 38 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 38 | 12 |
| Ibuprofen | Ibuprofen | 37 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | suppressed |
| Rytary | Carbidopa/Levodopa | 37 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | suppressed |
| Trulicity | Dulaglutide | 36 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 35 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 34 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 33 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 32 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | suppressed |
| Clonazepam | Clonazepam | 29 | suppressed |
| Naproxen | Naproxen | 29 | 11 |
| Latanoprost | Latanoprost | 28 | suppressed |
| Levetiracetam | Levetiracetam | 27 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 25 | suppressed |
| Pregabalin | Pregabalin | 25 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 24 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Lamotrigine | Lamotrigine | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Ramipril | Ramipril | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Olanzapine | Olanzapine | 22 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 14 |
| Levofloxacin | Levofloxacin | 21 | 15 |
| Rivastigmine | Rivastigmine Tartrate | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Budesonide | Budesonide | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 14 |
| Divalproex Sodium Er | Divalproex Sodium | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Trimethoprim | Trimethoprim | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | 12 |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 16 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Mounjaro | Tirzepatide | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | 12 |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Arformoterol Tartrate | Arformoterol Tartrate | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Carbamazepine Er | Carbamazepine | 14 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Constulose | Lactulose | 13 | suppressed |
| Jantoven | Warfarin Sodium | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 13 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 12 | suppressed |
| Repatha Syringe | Evolocumab | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Victoza 2-Pak | Liraglutide | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Armodafinil | Armodafinil | 11 | suppressed |
| Budesonide Dr | Budesonide | 11 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $400.28 · 23 records | ABBVIE INC. | AIRSUPRA, BREZTRI, CAPLYTA, Cologuard Collection Kit, ELIQUIS, FREESTYLE LIBRE 3, MOUNJARO, NURTEC ODT, OTEZLA, QULIPTA, REPATHA, UBRELVY, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET, ZENPEP | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error